Aurinia Pharmaceuticals (AUPH) valuation against sector peers: P/E 7.1 (sector median 25.8), P/B 3.4, P/S 6.9.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	AUPH	Sector median	vs median
P/E	7.1	25.8 · n=26	73% below
P/B	3.4	3.6 · n=45	6% below
P/S	6.9	4.7 · n=40	47% above
EV/EBIT	—	22.8 · n=28	—
Free-cash-flow yield	—	3.8% · n=39	—
Dividend yield	0.00%	0.19% · n=99	100% below
Return on equity	61.4%	5.2% · n=56	1,079% above
Return on invested capital	—	6.5% · n=47	—
Gross margin	90.6%	70.2% · n=39	29% above
Net debt / EBITDA	—	2.08 · n=25	—

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
NVSNovartis AG	22.3	6.8	18.7	5.6%	2.4%	10/10
NO NOVNNovartis AG	22.2	6.7	18.6	5.7%	2.8%	10/10
AZ AZNAstraZeneca PLC	28.7	6.0	23.1	4.0%	1.1%	5/10
AZ AZNAstraZeneca plc	28.6	6.0	23.0	4.0%	1.7%	6/10
NV NVONovo Nordisk A/S	12.0	6.3	10.4	4.8%	4.5%	8/10
SNYSanofi	13.4	1.5	18.2	6.9%	4.4%	7/10
SA SANSanofi SA	13.4	1.5	18.2	6.9%	4.8%	9/10
GS GSKGSK plc	14.4	5.0	11.7	7.8%	3.6%	9/10
TE TEVATeva Pharmaceutical Industries Limited	99.1	6.3	43.8	2.5%	0.0%	6/10
ALCAlcon	37.4	1.7	29.2	4.7%	0.4%	4/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 30 Oct 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings